[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFzWCup6q5V0h2skmEuvCrkdNl3kg9jbHKZNgRizrtjw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":82,"rows":89},"The First Affiliated Hospital of Xiamen University",[4],108,false,62,3,24497,58,44,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"PET\u002FCT",7,{"name":18,"count":19},"Positron-Emission Tomography",6,{"name":21,"count":22},"Follicular Lymphoma",4,{"name":24,"count":22},"Tumor",{"name":26,"count":9},"Prostate Cancer",{"name":28,"count":9},"Solid Tumor",{"name":30,"count":9},"Trop2",{"name":32,"count":9},"Ovarian Cancer",[34,39,44,49,54,59,64,68,72,77],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03087032","Liraglutide-bolus vs Glargine-bolus Therapy in Overweight\u002FObese Type 2 Diabetes Patients (LiraGooD)","2025-01-15","Liraglutide",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06068179","Graves' Disease Remission Study: MycoMeth Combo","2025-10-08","Mycophenolate Mofetil, Oral, 250 Mg",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06188455","Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer","2025-12-01","Fluzoparib",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03425812","Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission","2025-12-20","To withdraw NSAIDs therapy",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06375564","Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression","2025-12-30","177Lu-AB-3PRGD2 radioligand therapy",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06737523","Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R\u002FR AML","2025-12-31","CVA",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT06158412","All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory\u002FRelapsed Multiple Myeloma","All-trans Retinoic Acid in combination with the KPD Regimen",{"nctId":69,"briefTitle":70,"date":62,"intervention":71},"NCT07019181","Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma","Tislelizumab",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05305859","Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R\u002FR AML","2026-01-31","venetoclax combining chidamide and azacitidine",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06530004","Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children","2026-03-01","Rituximab",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,120,146,164,214,237,255,273,314,343,384,415,443,471,497,523,541,559,577,595,613,631,656,682,700,718,742,767,795,817,841,864,892,910,936,958,976,994,1021,1049,1067,1091,1112,1137,1160,1178,1196,1220,1246,1267,1288,1311,1337,1363,1388,1413,1436,1459,1477,1504,1522,1548,1566,1593,1611,1649,1671,1689,1707,1734,1752,1778,1796,1814,1832,1850,1874,1899,1917,1935,1953,1977,2002,2027,2053,2077,2107,2125,2143,2169,2194,2218,2241,2266],{"intervention":91,"totalTrials":92,"cells":93},"semaglutide combined with metformin",1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":118},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"NCT07165158","The Effect of Semaglutide on Bone Health","NOT_YET_RECRUITING",[87],"2026-12-31","2025-09-15",150,[114,115,116],"Osteoporosis","Osteoporosis Fracture","T2DM",[91],{"trials":119,"activeCount":96},[],{"intervention":38,"totalTrials":92,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":144},{"trials":123,"activeCount":96},[],{"trials":125,"activeCount":96},[],{"trials":127,"activeCount":96},[],{"trials":129,"activeCount":96},[],{"trials":131,"activeCount":92,"soonestReadout":37},[132],{"nctId":35,"briefTitle":36,"status":133,"phases":134,"primaryCompletion":37,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":142},"RECRUITING",[87],"2025-02-10","2019-01-10",164,[139,140,141],"Type 2 Diabetes Patients","Overweight and Obesity","Hyperglycaemia (Diabetic)",[38,143],"insulin glargine",{"trials":145,"activeCount":96},[],{"intervention":143,"totalTrials":92,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":96},[],{"trials":151,"activeCount":96},[],{"trials":153,"activeCount":96},[],{"trials":155,"activeCount":96},[],{"trials":157,"activeCount":92,"soonestReadout":37},[158],{"nctId":35,"briefTitle":36,"status":133,"phases":159,"primaryCompletion":37,"completion":135,"start":136,"enrollment":137,"conditions":160,"interventions":161},[87],[139,140,141],[38,143],{"trials":163,"activeCount":96},[],{"intervention":165,"totalTrials":9,"cells":166},"Apatinib Mesylate",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":201,"PHASE4":210,"NA":212},{"trials":168,"activeCount":96},[],{"trials":170,"activeCount":96},[],{"trials":172,"activeCount":92,"soonestReadout":177},[173,187],{"nctId":174,"briefTitle":175,"status":133,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT06415669","A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric\u002FGastroesophageal Junction Adenocarcinoma",[85],"2026-05-19","2027-05-19","2024-05-19",30,[182],"Gastric\u002FGastroesophageal Junction Adenocarcinoma",[184,185,186],"Paclitaxel for","Adebrelimab","Apatinib mesylate",{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT04572542","Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer","UNKNOWN",[84,85],"2021-06-01","2022-06-01","2020-01-01",46,[197],"Locally Advanced or Metastatic Gastric Adenocarcinoma",[199,165,200],"Camrelizumab","nab-paclitaxel",{"trials":202,"activeCount":92,"soonestReadout":47},[203],{"nctId":45,"briefTitle":46,"status":108,"phases":204,"primaryCompletion":47,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},[86],"2026-12-01","2024-12-01",37,[32],[48,165],{"trials":211,"activeCount":96},[],{"trials":213,"activeCount":96},[],{"intervention":43,"totalTrials":92,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":233,"NA":235},{"trials":217,"activeCount":96},[],{"trials":219,"activeCount":96},[],{"trials":221,"activeCount":96},[],{"trials":223,"activeCount":92,"soonestReadout":42},[224],{"nctId":40,"briefTitle":41,"status":133,"phases":225,"primaryCompletion":42,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":231},[85,86],"2026-10-08","2023-10-16",205,[230],"Graves' Disease",[43,232],"methimazole, oral, 10mg",{"trials":234,"activeCount":96},[],{"trials":236,"activeCount":96},[],{"intervention":232,"totalTrials":92,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":251,"NA":253},{"trials":240,"activeCount":96},[],{"trials":242,"activeCount":96},[],{"trials":244,"activeCount":96},[],{"trials":246,"activeCount":92,"soonestReadout":42},[247],{"nctId":40,"briefTitle":41,"status":133,"phases":248,"primaryCompletion":42,"completion":226,"start":227,"enrollment":228,"conditions":249,"interventions":250},[85,86],[230],[43,232],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"intervention":48,"totalTrials":92,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":269,"NA":271},{"trials":258,"activeCount":96},[],{"trials":260,"activeCount":96},[],{"trials":262,"activeCount":96},[],{"trials":264,"activeCount":92,"soonestReadout":47},[265],{"nctId":45,"briefTitle":46,"status":108,"phases":266,"primaryCompletion":47,"completion":205,"start":206,"enrollment":207,"conditions":267,"interventions":268},[86],[32],[48,165],{"trials":270,"activeCount":96},[],{"trials":272,"activeCount":96},[],{"intervention":71,"totalTrials":274,"cells":275},2,{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":96},[],{"trials":281,"activeCount":274,"soonestReadout":62},[282,299],{"nctId":283,"briefTitle":284,"status":133,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":293},"NCT06387056","Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)",[85],"2026-04-01","2029-04-01","2024-04-01",40,[291,292],"Locally Advanced Prostate Cancer","Oligometastatic Prostate Cancer",[294,295,296,297,298,71],"Rezvilutamide","Goserelin Microspheres for","Docetaxel","Pamiparib","Cisplatin",{"nctId":69,"briefTitle":70,"status":108,"phases":300,"primaryCompletion":62,"completion":110,"start":301,"enrollment":302,"conditions":303,"interventions":305},[85],"2025-07-30",26,[304],"Esophagus Cancer",[71,306,307],"albumin-bound paclitaxel","Nedaplatin",{"trials":309,"activeCount":96},[],{"trials":311,"activeCount":96},[],{"trials":313,"activeCount":96},[],{"intervention":185,"totalTrials":274,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":317,"activeCount":96},[],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":274,"soonestReadout":177},[322,326],{"nctId":174,"briefTitle":175,"status":133,"phases":323,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":324,"interventions":325},[85],[182],[184,185,186],{"nctId":327,"briefTitle":328,"status":108,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":336},"NCT07031154","A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer",[85],"2027-02-01","2025-06-30",43,[334,185,335],"Non-Small Cell Lung Cancer","Apatinib",[185,335],{"trials":338,"activeCount":96},[],{"trials":340,"activeCount":96},[],{"trials":342,"activeCount":96},[],{"intervention":344,"totalTrials":274,"cells":345},"Intravenous the dose of esketamine ED95",{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":347,"activeCount":96},[],{"trials":349,"activeCount":96},[],{"trials":351,"activeCount":274,"soonestReadout":357},[352,366],{"nctId":353,"briefTitle":354,"status":355,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":363},"NCT07034950","Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation","ACTIVE_NOT_RECRUITING",[84,85],"2028-06-30","2025-06-29",79,[361,362],"Hepatic Neoplasm","Hepatic Cancer",[364,344,365],"Intravenous esketamine using Dixon's up-and-down sequential method","Intravenous fentanyl 1 μg∙kg-1",{"nctId":367,"briefTitle":368,"status":355,"phases":369,"primaryCompletion":357,"completion":357,"start":370,"enrollment":371,"conditions":372,"interventions":375},"NCT07034963","Study on the Effective Dose and Safety of Esketamine in Hysteroscopic Surgery Under Monitored Anesthesia Care",[84,85],"2025-06-26",95,[373,374],"Intrauterine Polyp","Intrauterine Synechiae",[376,344,377],"Determine the ED50 and ED95 of esketamine","Intravenous remifentanil 1μg∙kg-1",{"trials":379,"activeCount":96},[],{"trials":381,"activeCount":96},[],{"trials":383,"activeCount":96},[],{"intervention":335,"totalTrials":274,"cells":385},{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":96},[],{"trials":391,"activeCount":92,"soonestReadout":330},[392,405],{"nctId":393,"briefTitle":394,"status":190,"phases":395,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":402},"NCT04425135","Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC",[85],"2023-01","2025-01","2020-07",59,[401],"Lung Neoplasms",[199,335,403,404],"Pemetrixed","Carboplatin",{"nctId":327,"briefTitle":328,"status":108,"phases":406,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":407,"interventions":408},[85],[334,185,335],[185,335],{"trials":410,"activeCount":96},[],{"trials":412,"activeCount":96},[],{"trials":414,"activeCount":96},[],{"intervention":416,"totalTrials":92,"cells":417},"IMRT combined with lobaplatin-based concurrent chemotherapy",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":419,"activeCount":96},[],{"trials":421,"activeCount":96},[],{"trials":423,"activeCount":92,"soonestReadout":110},[424],{"nctId":425,"briefTitle":426,"status":427,"phases":428,"primaryCompletion":110,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":436},"NCT06688175","IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma","ENROLLING_BY_INVITATION",[85],"2027-12-31","2024-11-13",32,[433,434,435],"Nasopharyngeal Neoplasms","Elderly","Chemotherapy",[416],{"trials":438,"activeCount":96},[],{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"intervention":444,"totalTrials":92,"cells":445},"TACE with adebrelimab and bevacizumab",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":447,"activeCount":96},[],{"trials":449,"activeCount":96},[],{"trials":451,"activeCount":92,"soonestReadout":456},[452],{"nctId":453,"briefTitle":454,"status":133,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":464},"NCT05970666","Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma",[85],"2026-11-15","2023-11-15",71,[185,460,461,462,463],"Hepatocellular Carcinoma","Transformation","Bevacizumab","TACE",[444],{"trials":466,"activeCount":96},[],{"trials":468,"activeCount":96},[],{"trials":470,"activeCount":96},[],{"intervention":472,"totalTrials":92,"cells":473},"CAR-T treatment",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":475,"activeCount":96},[],{"trials":477,"activeCount":96},[],{"trials":479,"activeCount":92,"soonestReadout":484},[480],{"nctId":481,"briefTitle":482,"status":133,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":490},"NCT06581640","Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed\u002FRefractory Multiple Myeloma",[85],"2028-12-31","2024-09-24",5,[488,489],"Multiple Myeloma","Relapsed\u002FRefractory",[472],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":96},[],{"trials":496,"activeCount":96},[],{"intervention":498,"totalTrials":92,"cells":499},"Adebrelimab+Albumin paclitaxel +Cisplatin",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":501,"activeCount":96},[],{"trials":503,"activeCount":96},[],{"trials":505,"activeCount":92,"soonestReadout":510},[506],{"nctId":507,"briefTitle":508,"status":108,"phases":509,"primaryCompletion":510,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT07137039","Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen",[85],"2027-08-20","2028-08-20","2025-08-20",34,[515],"Locally Advanced Hypopharyngeal Cancer",[498],{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":96},[],{"trials":522,"activeCount":96},[],{"intervention":294,"totalTrials":92,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":526,"activeCount":96},[],{"trials":528,"activeCount":96},[],{"trials":530,"activeCount":92,"soonestReadout":286},[531],{"nctId":283,"briefTitle":284,"status":133,"phases":532,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":533,"interventions":534},[85],[291,292],[294,295,296,297,298,71],{"trials":536,"activeCount":96},[],{"trials":538,"activeCount":96},[],{"trials":540,"activeCount":96},[],{"intervention":295,"totalTrials":92,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":544,"activeCount":96},[],{"trials":546,"activeCount":96},[],{"trials":548,"activeCount":92,"soonestReadout":286},[549],{"nctId":283,"briefTitle":284,"status":133,"phases":550,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":551,"interventions":552},[85],[291,292],[294,295,296,297,298,71],{"trials":554,"activeCount":96},[],{"trials":556,"activeCount":96},[],{"trials":558,"activeCount":96},[],{"intervention":296,"totalTrials":92,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":571,"PHASE4":573,"NA":575},{"trials":562,"activeCount":96},[],{"trials":564,"activeCount":96},[],{"trials":566,"activeCount":92,"soonestReadout":286},[567],{"nctId":283,"briefTitle":284,"status":133,"phases":568,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":569,"interventions":570},[85],[291,292],[294,295,296,297,298,71],{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":96},[],{"trials":576,"activeCount":96},[],{"intervention":297,"totalTrials":92,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":580,"activeCount":96},[],{"trials":582,"activeCount":96},[],{"trials":584,"activeCount":92,"soonestReadout":286},[585],{"nctId":283,"briefTitle":284,"status":133,"phases":586,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":587,"interventions":588},[85],[291,292],[294,295,296,297,298,71],{"trials":590,"activeCount":96},[],{"trials":592,"activeCount":96},[],{"trials":594,"activeCount":96},[],{"intervention":298,"totalTrials":92,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":598,"activeCount":96},[],{"trials":600,"activeCount":96},[],{"trials":602,"activeCount":92,"soonestReadout":286},[603],{"nctId":283,"briefTitle":284,"status":133,"phases":604,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":605,"interventions":606},[85],[291,292],[294,295,296,297,298,71],{"trials":608,"activeCount":96},[],{"trials":610,"activeCount":96},[],{"trials":612,"activeCount":96},[],{"intervention":184,"totalTrials":92,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":616,"activeCount":96},[],{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":92,"soonestReadout":177},[621],{"nctId":174,"briefTitle":175,"status":133,"phases":622,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":623,"interventions":624},[85],[182],[184,185,186],{"trials":626,"activeCount":96},[],{"trials":628,"activeCount":96},[],{"trials":630,"activeCount":96},[],{"intervention":632,"totalTrials":92,"cells":633},"Lenalidomide combined with G-CHOP",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":635,"activeCount":96},[],{"trials":637,"activeCount":96},[],{"trials":639,"activeCount":92,"soonestReadout":644},[640],{"nctId":641,"briefTitle":642,"status":133,"phases":643,"primaryCompletion":644,"completion":429,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT06151080","Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL",[85],"2027-08-31","2023-11-22",38,[648,21],"DLBCL - Diffuse Large B Cell Lymphoma",[632],{"trials":651,"activeCount":96},[],{"trials":653,"activeCount":96},[],{"trials":655,"activeCount":96},[],{"intervention":657,"totalTrials":92,"cells":658},"veneclax, chidaniline combined with azacitidine",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":660,"activeCount":96},[],{"trials":662,"activeCount":96},[],{"trials":664,"activeCount":92,"soonestReadout":669},[665],{"nctId":666,"briefTitle":667,"status":133,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT06827899","Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML",[85],"2026-06-30","2027-06-30","2022-07-01",66,[674],"Acute Myeloid Leukemia",[657],{"trials":677,"activeCount":96},[],{"trials":679,"activeCount":96},[],{"trials":681,"activeCount":96},[],{"intervention":364,"totalTrials":92,"cells":683},{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[],{"trials":689,"activeCount":92,"soonestReadout":357},[690],{"nctId":353,"briefTitle":354,"status":355,"phases":691,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":692,"interventions":693},[84,85],[361,362],[364,344,365],{"trials":695,"activeCount":96},[],{"trials":697,"activeCount":96},[],{"trials":699,"activeCount":96},[],{"intervention":365,"totalTrials":92,"cells":701},{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":92,"soonestReadout":357},[708],{"nctId":353,"briefTitle":354,"status":355,"phases":709,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":710,"interventions":711},[84,85],[361,362],[364,344,365],{"trials":713,"activeCount":96},[],{"trials":715,"activeCount":96},[],{"trials":717,"activeCount":96},[],{"intervention":719,"totalTrials":92,"cells":720},"Axicabtagene Ciloleucel",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":722,"activeCount":96},[],{"trials":724,"activeCount":96},[],{"trials":726,"activeCount":92,"soonestReadout":110},[727],{"nctId":728,"briefTitle":729,"status":133,"phases":730,"primaryCompletion":110,"completion":110,"start":731,"enrollment":180,"conditions":732,"interventions":735},"NCT06826118","Axicabtagene Ciloleucel Injection in Patients With Relapsed\u002FRefractory Follicular Lymphoma",[85],"2025-02-08",[733,21,734],"Lymphoma","Refractory Lymphoma",[719],{"trials":737,"activeCount":96},[],{"trials":739,"activeCount":96},[],{"trials":741,"activeCount":96},[],{"intervention":743,"totalTrials":92,"cells":744},"Zanubrutinib combined with Obinutuzumab",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":746,"activeCount":96},[],{"trials":748,"activeCount":96},[],{"trials":750,"activeCount":92,"soonestReadout":755},[751],{"nctId":752,"briefTitle":753,"status":133,"phases":754,"primaryCompletion":755,"completion":644,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT06553352","Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma",[85],"2026-04-20","2024-03-31",39,[21,759],"Newly Diagnosed",[743],{"trials":762,"activeCount":96},[],{"trials":764,"activeCount":96},[],{"trials":766,"activeCount":96},[],{"intervention":768,"totalTrials":92,"cells":769},"Trilaciclib and Sacituzumab Tirumotecan",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":92,"soonestReadout":780},[776],{"nctId":777,"briefTitle":778,"status":133,"phases":779,"primaryCompletion":780,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":788},"NCT06992739","Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)",[85],"2027-03","2027-12","2025-12-08",49,[785,786,787],"NSCLC (Advanced Non-small Cell Lung Cancer)","EGFR","Myelosuppression",[768],{"trials":790,"activeCount":96},[],{"trials":792,"activeCount":96},[],{"trials":794,"activeCount":96},[],{"intervention":76,"totalTrials":92,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":798,"activeCount":96},[],{"trials":800,"activeCount":96},[],{"trials":802,"activeCount":92,"soonestReadout":75},[803],{"nctId":73,"briefTitle":74,"status":133,"phases":804,"primaryCompletion":75,"completion":670,"start":805,"enrollment":180,"conditions":806,"interventions":810},[85],"2022-01-12",[807,808,809],"Leukemia, Myeloid, Acute","Relapsed Adult AML","Refractory Leukemia",[76],{"trials":812,"activeCount":96},[],{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"intervention":818,"totalTrials":92,"cells":819},"Chidamide combined with Linperlisib",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":821,"activeCount":96},[],{"trials":823,"activeCount":96},[],{"trials":825,"activeCount":92,"soonestReadout":429},[826],{"nctId":827,"briefTitle":828,"status":133,"phases":829,"primaryCompletion":429,"completion":429,"start":645,"enrollment":830,"conditions":831,"interventions":834},"NCT06158386","Chidamide Combined With Linperlisibon for the Treatment of Refractory\u002FRelapsed Follicular Lymphoma",[85],33,[21,832,833],"Refractory B-Cell Lymphoma","Relapsed Non-Hodgkin Lymphoma",[818],{"trials":836,"activeCount":96},[],{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":96},[],{"intervention":842,"totalTrials":92,"cells":843},"Pyrotinib Maleate Tablets + Dalpiciclib Isethionate Tablets + Standard Endocrine",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":858,"PHASE4":860,"NA":862},{"trials":845,"activeCount":96},[],{"trials":847,"activeCount":96},[],{"trials":849,"activeCount":92,"soonestReadout":669},[850],{"nctId":851,"briefTitle":852,"status":108,"phases":853,"primaryCompletion":669,"completion":484,"start":854,"enrollment":830,"conditions":855,"interventions":857},"NCT07189884","Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy",[84,85],"2025-09-23",[856],"Locally Advanced Breast Cancer (LABC)",[842],{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"intervention":865,"totalTrials":92,"cells":866},"Two-cycle induction chemotherapy + immunotherapy",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":868,"activeCount":96},[],{"trials":870,"activeCount":96},[],{"trials":872,"activeCount":92,"soonestReadout":429},[873],{"nctId":874,"briefTitle":875,"status":133,"phases":876,"primaryCompletion":429,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":884},"NCT06811844","Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC",[85],"2029-12-31","2025-02-25",208,[433,881,882,883,435],"PD-1 Inhibitor","Induction Therapy","Complete Response",[865,885],"Three-cycle induction chemotherapy + immunotherapy",{"trials":887,"activeCount":96},[],{"trials":889,"activeCount":96},[],{"trials":891,"activeCount":96},[],{"intervention":885,"totalTrials":92,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":895,"activeCount":96},[],{"trials":897,"activeCount":96},[],{"trials":899,"activeCount":92,"soonestReadout":429},[900],{"nctId":874,"briefTitle":875,"status":133,"phases":901,"primaryCompletion":429,"completion":877,"start":878,"enrollment":879,"conditions":902,"interventions":903},[85],[433,881,882,883,435],[865,885],{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[],{"trials":909,"activeCount":96},[],{"intervention":911,"totalTrials":92,"cells":912},"SBRT combined with Nimotuzumab followed by Tislelizumab",{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":914,"activeCount":96},[],{"trials":916,"activeCount":96},[],{"trials":918,"activeCount":92,"soonestReadout":110},[919],{"nctId":920,"briefTitle":921,"status":133,"phases":922,"primaryCompletion":110,"completion":429,"start":923,"enrollment":924,"conditions":925,"interventions":929},"NCT06676722","SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent\u002FMetastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy",[85],"2024-11-05",20,[926,927,928],"Nasopharyngeal Cancinoma (NPC)","SBRT","Immunotherapy",[911],{"trials":931,"activeCount":96},[],{"trials":933,"activeCount":96},[],{"trials":935,"activeCount":96},[],{"intervention":937,"totalTrials":92,"cells":938},"Iparomlimab\u002FTuvorlimab(QL-1706) and modified TPF regimen",{"EARLY_PHASE1":939,"PHASE1":941,"PHASE2":943,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":940,"activeCount":96},[],{"trials":942,"activeCount":96},[],{"trials":944,"activeCount":92,"soonestReadout":429},[945],{"nctId":946,"briefTitle":947,"status":133,"phases":948,"primaryCompletion":429,"completion":877,"start":301,"enrollment":180,"conditions":949,"interventions":951},"NCT07085234","Iparomlimab\u002FTuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC",[85],[950,928,882],"Locally Advanced Nasopharyngeal Carcinoma",[937],{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"intervention":376,"totalTrials":92,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":961,"activeCount":96},[],{"trials":963,"activeCount":96},[],{"trials":965,"activeCount":92,"soonestReadout":357},[966],{"nctId":367,"briefTitle":368,"status":355,"phases":967,"primaryCompletion":357,"completion":357,"start":370,"enrollment":371,"conditions":968,"interventions":969},[84,85],[373,374],[376,344,377],{"trials":971,"activeCount":96},[],{"trials":973,"activeCount":96},[],{"trials":975,"activeCount":96},[],{"intervention":377,"totalTrials":92,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":979,"activeCount":96},[],{"trials":981,"activeCount":96},[],{"trials":983,"activeCount":92,"soonestReadout":357},[984],{"nctId":367,"briefTitle":368,"status":355,"phases":985,"primaryCompletion":357,"completion":357,"start":370,"enrollment":371,"conditions":986,"interventions":987},[84,85],[373,374],[376,344,377],{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[],{"intervention":995,"totalTrials":92,"cells":996},"Tofacitinib",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":998,"activeCount":96},[],{"trials":1000,"activeCount":96},[],{"trials":1002,"activeCount":92,"soonestReadout":1007},[1003],{"nctId":1004,"briefTitle":1005,"status":133,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1014},"NCT07547930","Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease",[85],"2027-12-30","2026-04-24",8,[1011,1012,1013],"Thyroid Eye Disease, TED","Graves Ophthalmopathy","Graves Orbitopathy",[995],{"trials":1016,"activeCount":96},[],{"trials":1018,"activeCount":96},[],{"trials":1020,"activeCount":96},[],{"intervention":1022,"totalTrials":92,"cells":1023},"Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1025,"activeCount":96},[],{"trials":1027,"activeCount":96},[],{"trials":1029,"activeCount":92,"soonestReadout":1034},[1030],{"nctId":1031,"briefTitle":1032,"status":133,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1041},"NCT06584006","Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors",[85],"2027-11-30","2028-02-29","2024-09-01",50,[1039,1040],"Hematological Malignancy","Lymphocytopenia",[1022,1042],"Recombinant Human Interleukin-2 Injections",{"trials":1044,"activeCount":96},[],{"trials":1046,"activeCount":96},[],{"trials":1048,"activeCount":96},[],{"intervention":1042,"totalTrials":92,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1052,"activeCount":96},[],{"trials":1054,"activeCount":96},[],{"trials":1056,"activeCount":92,"soonestReadout":1034},[1057],{"nctId":1031,"briefTitle":1032,"status":133,"phases":1058,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1059,"interventions":1060},[85],[1039,1040],[1022,1042],{"trials":1062,"activeCount":96},[],{"trials":1064,"activeCount":96},[],{"trials":1066,"activeCount":96},[],{"intervention":1068,"totalTrials":92,"cells":1069},"Azacitidine in combination with R-CHOP",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1085,"PHASE4":1087,"NA":1089},{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":92,"soonestReadout":1080},[1076],{"nctId":1077,"briefTitle":1078,"status":133,"phases":1079,"primaryCompletion":1080,"completion":1080,"start":645,"enrollment":1081,"conditions":1082,"interventions":1084},"NCT06158399","AZA Combined With RCHOP in P53-mutated DLBCL.",[85],"2026-05-31",52,[648,1083],"TP53",[1068],{"trials":1086,"activeCount":96},[],{"trials":1088,"activeCount":96},[],{"trials":1090,"activeCount":96},[],{"intervention":67,"totalTrials":92,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1094,"activeCount":96},[],{"trials":1096,"activeCount":96},[],{"trials":1098,"activeCount":92,"soonestReadout":62},[1099],{"nctId":65,"briefTitle":66,"status":133,"phases":1100,"primaryCompletion":62,"completion":62,"start":645,"enrollment":1101,"conditions":1102,"interventions":1105},[85],25,[1103,1104],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory",[67],{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":96},[],{"intervention":1113,"totalTrials":92,"cells":1114},"Chidamide combined with Duvillisib",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1116,"activeCount":96},[],{"trials":1118,"activeCount":96},[],{"trials":1120,"activeCount":92,"soonestReadout":110},[1121],{"nctId":1122,"briefTitle":1123,"status":133,"phases":1124,"primaryCompletion":110,"completion":1125,"start":645,"enrollment":830,"conditions":1126,"interventions":1130},"NCT06151106","Chidamide and Duvalisibon for the Treatment of Refractory\u002FRelapsed Peripheral T-cell Lymphoma",[85],"2027-12-25",[1127,1128,1129],"Peripheral T Cell Lymphoma","Relapsed Peripheral T-Cell Lymphoma","Refractory T-Cell Lymphoma",[1113],{"trials":1132,"activeCount":96},[],{"trials":1134,"activeCount":96},[],{"trials":1136,"activeCount":96},[],{"intervention":1138,"totalTrials":92,"cells":1139},"Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1141,"activeCount":96},[],{"trials":1143,"activeCount":96},[],{"trials":1145,"activeCount":92,"soonestReadout":110},[1146],{"nctId":1147,"briefTitle":1148,"status":133,"phases":1149,"primaryCompletion":110,"completion":110,"start":1150,"enrollment":672,"conditions":1151,"interventions":1153},"NCT05603884","VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)",[85],"2022-12-01",[807,1152],"AML Stage, Adult",[1138],{"trials":1155,"activeCount":96},[],{"trials":1157,"activeCount":96},[],{"trials":1159,"activeCount":96},[],{"intervention":306,"totalTrials":92,"cells":1161},{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1163,"activeCount":96},[],{"trials":1165,"activeCount":96},[],{"trials":1167,"activeCount":92,"soonestReadout":62},[1168],{"nctId":69,"briefTitle":70,"status":108,"phases":1169,"primaryCompletion":62,"completion":110,"start":301,"enrollment":302,"conditions":1170,"interventions":1171},[85],[304],[71,306,307],{"trials":1173,"activeCount":96},[],{"trials":1175,"activeCount":96},[],{"trials":1177,"activeCount":96},[],{"intervention":307,"totalTrials":92,"cells":1179},{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1181,"activeCount":96},[],{"trials":1183,"activeCount":96},[],{"trials":1185,"activeCount":92,"soonestReadout":62},[1186],{"nctId":69,"briefTitle":70,"status":108,"phases":1187,"primaryCompletion":62,"completion":110,"start":301,"enrollment":302,"conditions":1188,"interventions":1189},[85],[304],[71,306,307],{"trials":1191,"activeCount":96},[],{"trials":1193,"activeCount":96},[],{"trials":1195,"activeCount":96},[],{"intervention":1197,"totalTrials":92,"cells":1198},"Trilaciclib combined with Docetaxel",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1214,"PHASE4":1216,"NA":1218},{"trials":1200,"activeCount":96},[],{"trials":1202,"activeCount":96},[],{"trials":1204,"activeCount":92,"soonestReadout":1209},[1205],{"nctId":1206,"briefTitle":1207,"status":133,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":830,"conditions":1212,"interventions":1213},"NCT06929936","Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC",[85],"2026-05","2026-06","2025-05-09",[334,787],[1197],{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":96},[],{"trials":1219,"activeCount":96},[],{"intervention":1221,"totalTrials":92,"cells":1222},"Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab",{"EARLY_PHASE1":1223,"PHASE1":1225,"PHASE2":1227,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1224,"activeCount":96},[],{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":92,"soonestReadout":429},[1229],{"nctId":1230,"briefTitle":1231,"status":133,"phases":1232,"primaryCompletion":429,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1239},"NCT06651853","Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL",[85],"2028-07-30","2024-10-21",22,[1237,1238],"Diffuse Large B-cell Lymphoma","Relapsed and Refractory",[1221],{"trials":1241,"activeCount":96},[],{"trials":1243,"activeCount":96},[],{"trials":1245,"activeCount":96},[],{"intervention":63,"totalTrials":92,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1259,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1249,"activeCount":96},[],{"trials":1251,"activeCount":92,"soonestReadout":62},[1252],{"nctId":60,"briefTitle":61,"status":133,"phases":1253,"primaryCompletion":62,"completion":110,"start":1254,"enrollment":180,"conditions":1255,"interventions":1258},[84],"2025-03-15",[674,1256,1257],"Relapse","Refractory AML",[63],{"trials":1260,"activeCount":96},[],{"trials":1262,"activeCount":96},[],{"trials":1264,"activeCount":96},[],{"trials":1266,"activeCount":96},[],{"intervention":58,"totalTrials":92,"cells":1268},{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":92,"soonestReadout":57},[1273],{"nctId":55,"briefTitle":56,"status":133,"phases":1274,"primaryCompletion":57,"completion":1275,"start":1276,"enrollment":924,"conditions":1277,"interventions":1279},[84],"2026-12-30","2024-06-12",[1278],"Refractory Solid Tumor",[58],{"trials":1281,"activeCount":96},[],{"trials":1283,"activeCount":96},[],{"trials":1285,"activeCount":96},[],{"trials":1287,"activeCount":96},[],{"intervention":1289,"totalTrials":92,"cells":1290},"D-CMG",{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1292,"activeCount":96},[],{"trials":1294,"activeCount":92,"soonestReadout":110},[1295],{"nctId":1296,"briefTitle":1297,"status":133,"phases":1298,"primaryCompletion":110,"completion":670,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1302},"NCT06651866","Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients",[84],"2024-12-12",18,[674],[1289],{"trials":1304,"activeCount":96},[],{"trials":1306,"activeCount":96},[],{"trials":1308,"activeCount":96},[],{"trials":1310,"activeCount":96},[],{"intervention":1312,"totalTrials":92,"cells":1313},"GB5005 CART",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1315,"activeCount":96},[],{"trials":1317,"activeCount":92,"soonestReadout":1080},[1318],{"nctId":1319,"briefTitle":1320,"status":133,"phases":1321,"primaryCompletion":1080,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1328},"NCT06875063","GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL",[84],"2027-05-31","2026-04-30",45,[1326,734,1327],"Non-hodgkin Lymphoma","Chimeric Antigen Receptor T-cell",[1312],{"trials":1330,"activeCount":96},[],{"trials":1332,"activeCount":96},[],{"trials":1334,"activeCount":96},[],{"trials":1336,"activeCount":96},[],{"intervention":1338,"totalTrials":92,"cells":1339},"yFMT",{"EARLY_PHASE1":1340,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1341,"activeCount":92,"soonestReadout":1346},[1342],{"nctId":1343,"briefTitle":1344,"status":108,"phases":1345,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":1348,"conditions":1349,"interventions":1352},"NCT07486492","Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer",[83],"2028-01-31","2026-03-31",10,[1350,1351],"Colorectal Cancer Metastatic","Fecal Microbiota Transplantation",[1338],{"trials":1354,"activeCount":96},[],{"trials":1356,"activeCount":96},[],{"trials":1358,"activeCount":96},[],{"trials":1360,"activeCount":96},[],{"trials":1362,"activeCount":96},[],{"intervention":1364,"totalTrials":92,"cells":1365},"Peginterferon α-2b plus an anti-PD-1",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1367,"activeCount":96},[],{"trials":1369,"activeCount":96},[],{"trials":1371,"activeCount":96},[],{"trials":1373,"activeCount":96},[],{"trials":1375,"activeCount":96},[],{"trials":1377,"activeCount":92,"soonestReadout":1382},[1378],{"nctId":1379,"briefTitle":1380,"status":108,"phases":1381,"primaryCompletion":1382,"completion":781,"start":1383,"enrollment":1384,"conditions":1385,"interventions":1387},"NCT07438093","Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors",[88],"2027-04","2026-04",60,[1386],"Advanced Solid Tumors",[1364,1364,1364],{"intervention":1389,"totalTrials":92,"cells":1390},"Orelabrutinib in combination with rituximab",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1397,"PHASE4":1399,"NA":1401},{"trials":1392,"activeCount":96},[],{"trials":1394,"activeCount":96},[],{"trials":1396,"activeCount":96},[],{"trials":1398,"activeCount":96},[],{"trials":1400,"activeCount":96},[],{"trials":1402,"activeCount":92,"soonestReadout":1407},[1403],{"nctId":1404,"briefTitle":1405,"status":133,"phases":1406,"primaryCompletion":1407,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT06478472","Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy",[88],"2027-06-23","2024-06-23",36,[1411],"Marginal Zone Lymphoma",[1389],{"intervention":81,"totalTrials":92,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1425},{"trials":1416,"activeCount":96},[],{"trials":1418,"activeCount":96},[],{"trials":1420,"activeCount":96},[],{"trials":1422,"activeCount":96},[],{"trials":1424,"activeCount":96},[],{"trials":1426,"activeCount":92,"soonestReadout":80},[1427],{"nctId":78,"briefTitle":79,"status":133,"phases":1428,"primaryCompletion":80,"completion":1429,"start":1430,"enrollment":1037,"conditions":1431,"interventions":1435},[],"2028-03-01","2020-03-01",[1432,81,1433,1434],"Nephrotic Syndrome","Children","Efficacy",[81],{"intervention":53,"totalTrials":92,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1439,"activeCount":96},[],{"trials":1441,"activeCount":96},[],{"trials":1443,"activeCount":96},[],{"trials":1445,"activeCount":96},[],{"trials":1447,"activeCount":96},[],{"trials":1449,"activeCount":92,"soonestReadout":52},[1450],{"nctId":50,"briefTitle":51,"status":133,"phases":1451,"primaryCompletion":52,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1457},[88],"2028-12-20","2018-02-15",140,[1456],"Axial Spondyloarthritis",[53,1458],"To continue NSAIDs therapy",{"intervention":1458,"totalTrials":92,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1462,"activeCount":96},[],{"trials":1464,"activeCount":96},[],{"trials":1466,"activeCount":96},[],{"trials":1468,"activeCount":96},[],{"trials":1470,"activeCount":96},[],{"trials":1472,"activeCount":92,"soonestReadout":52},[1473],{"nctId":50,"briefTitle":51,"status":133,"phases":1474,"primaryCompletion":52,"completion":1452,"start":1453,"enrollment":1454,"conditions":1475,"interventions":1476},[88],[1456],[53,1458],{"intervention":1478,"totalTrials":92,"cells":1479},"insulin lispro injection, exenatide",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1502},{"trials":1481,"activeCount":96},[],{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[],{"trials":1487,"activeCount":96},[],{"trials":1489,"activeCount":96},[1490],{"nctId":1491,"briefTitle":1492,"status":1493,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1500},"NCT01776788","Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients","COMPLETED",[87],"2015-02","2012-08",156,[1499],"Diabetes Mellitus, Type 2",[1478,1501],"insulin lispro",{"trials":1503,"activeCount":96},[],{"intervention":1501,"totalTrials":92,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1520},{"trials":1507,"activeCount":96},[],{"trials":1509,"activeCount":96},[],{"trials":1511,"activeCount":96},[],{"trials":1513,"activeCount":96},[],{"trials":1515,"activeCount":96},[1516],{"nctId":1491,"briefTitle":1492,"status":1493,"phases":1517,"primaryCompletion":1495,"completion":1495,"start":1496,"enrollment":1497,"conditions":1518,"interventions":1519},[87],[1499],[1478,1501],{"trials":1521,"activeCount":96},[],{"intervention":1523,"totalTrials":92,"cells":1524},"CSII+Vildagliptin",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1546},{"trials":1526,"activeCount":96},[],{"trials":1528,"activeCount":96},[],{"trials":1530,"activeCount":96},[],{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[1535],{"nctId":1536,"briefTitle":1537,"status":190,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1543,"interventions":1544},"NCT03563794","Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes",[87],"2019-06-10","2019-12-10","2018-06-10",400,[116],[1523,1545],"CSII",{"trials":1547,"activeCount":96},[],{"intervention":1545,"totalTrials":92,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1564},{"trials":1551,"activeCount":96},[],{"trials":1553,"activeCount":96},[],{"trials":1555,"activeCount":96},[],{"trials":1557,"activeCount":96},[],{"trials":1559,"activeCount":96},[1560],{"nctId":1536,"briefTitle":1537,"status":190,"phases":1561,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1542,"conditions":1562,"interventions":1563},[87],[116],[1523,1545],{"trials":1565,"activeCount":96},[],{"intervention":1567,"totalTrials":92,"cells":1568},"Normal Saline",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1575,"PHASE4":1589,"NA":1591},{"trials":1570,"activeCount":96},[],{"trials":1572,"activeCount":96},[],{"trials":1574,"activeCount":96},[],{"trials":1576,"activeCount":96},[1577],{"nctId":1578,"briefTitle":1579,"status":190,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1587},"NCT06281561","Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance",[86],"2024-11-30","2024-12-31","2024-05-01",110,[1586],"Postoperative Sleep Disturbance",[1567,1588],"Dexmedetomidine",{"trials":1590,"activeCount":96},[],{"trials":1592,"activeCount":96},[],{"intervention":1588,"totalTrials":92,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1607,"NA":1609},{"trials":1596,"activeCount":96},[],{"trials":1598,"activeCount":96},[],{"trials":1600,"activeCount":96},[],{"trials":1602,"activeCount":96},[1603],{"nctId":1578,"briefTitle":1579,"status":190,"phases":1604,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":1584,"conditions":1605,"interventions":1606},[86],[1586],[1567,1588],{"trials":1608,"activeCount":96},[],{"trials":1610,"activeCount":96},[],{"intervention":1612,"totalTrials":274,"cells":1613},"Sintilimab",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1615,"activeCount":96},[],{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[1620,1630],{"nctId":1621,"briefTitle":1622,"status":190,"phases":1623,"primaryCompletion":1624,"completion":1625,"start":1626,"enrollment":757,"conditions":1627,"interventions":1629},"NCT04840758","Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer",[84,85],"2022-12","2023-04","2021-06",[1628],"Multiple Primary Lung Cancer",[1612],{"nctId":1631,"briefTitle":1632,"status":190,"phases":1633,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":458,"conditions":1637,"interventions":1639},"NCT05292417","Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC",[85],"2023-03","2024-03","2022-03-25",[1638],"Colorectal Neoplasms",[1640,1641,1642],"sintilimab","GM-CSF","Fruquintinib",{"trials":1644,"activeCount":96},[],{"trials":1646,"activeCount":96},[],{"trials":1648,"activeCount":96},[],{"intervention":199,"totalTrials":274,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[1657,1661],{"nctId":393,"briefTitle":394,"status":190,"phases":1658,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":1659,"interventions":1660},[85],[401],[199,335,403,404],{"nctId":188,"briefTitle":189,"status":190,"phases":1662,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":1663,"interventions":1664},[84,85],[197],[199,165,200],{"trials":1666,"activeCount":96},[],{"trials":1668,"activeCount":96},[],{"trials":1670,"activeCount":96},[],{"intervention":403,"totalTrials":92,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":96},[],{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":96},[1679],{"nctId":393,"briefTitle":394,"status":190,"phases":1680,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":1681,"interventions":1682},[85],[401],[199,335,403,404],{"trials":1684,"activeCount":96},[],{"trials":1686,"activeCount":96},[],{"trials":1688,"activeCount":96},[],{"intervention":404,"totalTrials":92,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1692,"activeCount":96},[],{"trials":1694,"activeCount":96},[],{"trials":1696,"activeCount":96},[1697],{"nctId":393,"briefTitle":394,"status":190,"phases":1698,"primaryCompletion":396,"completion":397,"start":398,"enrollment":399,"conditions":1699,"interventions":1700},[85],[401],[199,335,403,404],{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[],{"intervention":1708,"totalTrials":92,"cells":1709},"Immunological Agent",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1711,"activeCount":96},[],{"trials":1713,"activeCount":96},[],{"trials":1715,"activeCount":96},[1716],{"nctId":1717,"briefTitle":1718,"status":190,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1726},"NCT02976740","SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy",[85],"2019-06","2019-12","2016-11",48,[1725],"Lung Cancer Metastatic",[1708,1727],"Immunological Factors",{"trials":1729,"activeCount":96},[],{"trials":1731,"activeCount":96},[],{"trials":1733,"activeCount":96},[],{"intervention":1727,"totalTrials":92,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1737,"activeCount":96},[],{"trials":1739,"activeCount":96},[],{"trials":1741,"activeCount":96},[1742],{"nctId":1717,"briefTitle":1718,"status":190,"phases":1743,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":1723,"conditions":1744,"interventions":1745},[85],[1725],[1708,1727],{"trials":1747,"activeCount":96},[],{"trials":1749,"activeCount":96},[],{"trials":1751,"activeCount":96},[],{"intervention":1753,"totalTrials":92,"cells":1754},"177Lu-LNC1010 1",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1756,"activeCount":96},[],{"trials":1758,"activeCount":96},[],{"trials":1760,"activeCount":96},[1761],{"nctId":1762,"briefTitle":1763,"status":1493,"phases":1764,"primaryCompletion":1765,"completion":1765,"start":193,"enrollment":180,"conditions":1766,"interventions":1768},"NCT05410743","Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors",[84,85],"2025-03-24",[1767],"SSTR2-positive Tumors",[1753,1769,1770,1771],"177Lu-LNC1010 2","177Lu-LNC1010 3","177Lu-LNC1010 4",{"trials":1773,"activeCount":96},[],{"trials":1775,"activeCount":96},[],{"trials":1777,"activeCount":96},[],{"intervention":1769,"totalTrials":92,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":96},[1786],{"nctId":1762,"briefTitle":1763,"status":1493,"phases":1787,"primaryCompletion":1765,"completion":1765,"start":193,"enrollment":180,"conditions":1788,"interventions":1789},[84,85],[1767],[1753,1769,1770,1771],{"trials":1791,"activeCount":96},[],{"trials":1793,"activeCount":96},[],{"trials":1795,"activeCount":96},[],{"intervention":1770,"totalTrials":92,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[1804],{"nctId":1762,"briefTitle":1763,"status":1493,"phases":1805,"primaryCompletion":1765,"completion":1765,"start":193,"enrollment":180,"conditions":1806,"interventions":1807},[84,85],[1767],[1753,1769,1770,1771],{"trials":1809,"activeCount":96},[],{"trials":1811,"activeCount":96},[],{"trials":1813,"activeCount":96},[],{"intervention":1771,"totalTrials":92,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":96},[],{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":96},[1822],{"nctId":1762,"briefTitle":1763,"status":1493,"phases":1823,"primaryCompletion":1765,"completion":1765,"start":193,"enrollment":180,"conditions":1824,"interventions":1825},[84,85],[1767],[1753,1769,1770,1771],{"trials":1827,"activeCount":96},[],{"trials":1829,"activeCount":96},[],{"trials":1831,"activeCount":96},[],{"intervention":200,"totalTrials":92,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":96},[],{"trials":1837,"activeCount":96},[],{"trials":1839,"activeCount":96},[1840],{"nctId":188,"briefTitle":189,"status":190,"phases":1841,"primaryCompletion":192,"completion":193,"start":194,"enrollment":195,"conditions":1842,"interventions":1843},[84,85],[197],[199,165,200],{"trials":1845,"activeCount":96},[],{"trials":1847,"activeCount":96},[],{"trials":1849,"activeCount":96},[],{"intervention":1851,"totalTrials":92,"cells":1852},"Toripalimab",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1868,"PHASE4":1870,"NA":1872},{"trials":1854,"activeCount":96},[],{"trials":1856,"activeCount":96},[],{"trials":1858,"activeCount":96},[1859],{"nctId":1860,"briefTitle":1861,"status":190,"phases":1862,"primaryCompletion":1863,"completion":1863,"start":1864,"enrollment":180,"conditions":1865,"interventions":1867},"NCT04389151","Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer",[85],"2021-03-04","2020-03-04",[1866],"Locally Advanced Colon Cancer",[1851],{"trials":1869,"activeCount":96},[],{"trials":1871,"activeCount":96},[],{"trials":1873,"activeCount":96},[],{"intervention":1875,"totalTrials":92,"cells":1876},"Zoladex",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1878,"activeCount":96},[],{"trials":1880,"activeCount":96},[],{"trials":1882,"activeCount":96},[1883],{"nctId":1884,"briefTitle":1885,"status":190,"phases":1886,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1384,"conditions":1890,"interventions":1891},"NCT06385847","To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer",[85],"2025-05","2025-12","2024-05",[26],[1875,1892],"LY01005",{"trials":1894,"activeCount":96},[],{"trials":1896,"activeCount":96},[],{"trials":1898,"activeCount":96},[],{"intervention":1892,"totalTrials":92,"cells":1900},{"EARLY_PHASE1":1901,"PHASE1":1903,"PHASE2":1905,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1902,"activeCount":96},[],{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[1907],{"nctId":1884,"briefTitle":1885,"status":190,"phases":1908,"primaryCompletion":1887,"completion":1888,"start":1889,"enrollment":1384,"conditions":1909,"interventions":1910},[85],[26],[1875,1892],{"trials":1912,"activeCount":96},[],{"trials":1914,"activeCount":96},[],{"trials":1916,"activeCount":96},[],{"intervention":1641,"totalTrials":92,"cells":1918},{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1929,"PHASE4":1931,"NA":1933},{"trials":1920,"activeCount":96},[],{"trials":1922,"activeCount":96},[],{"trials":1924,"activeCount":96},[1925],{"nctId":1631,"briefTitle":1632,"status":190,"phases":1926,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":458,"conditions":1927,"interventions":1928},[85],[1638],[1640,1641,1642],{"trials":1930,"activeCount":96},[],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"intervention":1642,"totalTrials":92,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":96},[],{"trials":1940,"activeCount":96},[],{"trials":1942,"activeCount":96},[1943],{"nctId":1631,"briefTitle":1632,"status":190,"phases":1944,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":458,"conditions":1945,"interventions":1946},[85],[1638],[1640,1641,1642],{"trials":1948,"activeCount":96},[],{"trials":1950,"activeCount":96},[],{"trials":1952,"activeCount":96},[],{"intervention":1954,"totalTrials":92,"cells":1955},"Envafolimab",{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"trials":1961,"activeCount":96},[1962],{"nctId":1963,"briefTitle":1964,"status":190,"phases":1965,"primaryCompletion":1966,"completion":331,"start":1967,"enrollment":924,"conditions":1968,"interventions":1970},"NCT05055167","Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC",[85],"2024-12-30","2021-08-30",[1969],"Non-small Cell Lung Cancer Stage IV",[1954],{"trials":1972,"activeCount":96},[],{"trials":1974,"activeCount":96},[],{"trials":1976,"activeCount":96},[],{"intervention":1978,"totalTrials":92,"cells":1979},"177Lu-DOTA-EB-FAPI radionuclide therapy",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1981,"activeCount":96},[],{"trials":1983,"activeCount":96},[],{"trials":1985,"activeCount":96},[1986],{"nctId":1987,"briefTitle":1988,"status":1493,"phases":1989,"primaryCompletion":1990,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1995},"NCT05963386","Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors",[85],"2024-09-15","2024-10-05","2022-02-22",28,[1278],[1978],{"trials":1997,"activeCount":96},[],{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[],{"intervention":2003,"totalTrials":92,"cells":2004},"Pemigatinib",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2021,"PHASE4":2023,"NA":2025},{"trials":2006,"activeCount":96},[],{"trials":2008,"activeCount":96},[],{"trials":2010,"activeCount":96},[2011],{"nctId":2012,"briefTitle":2013,"status":190,"phases":2014,"primaryCompletion":2015,"completion":2016,"start":2017,"enrollment":924,"conditions":2018,"interventions":2020},"NCT05287386","A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy",[85],"2024-01-21","2025-01-21","2022-01-21",[2019],"Advanced Non-Small Cell Lung Cancer",[2003],{"trials":2022,"activeCount":96},[],{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"intervention":2028,"totalTrials":92,"cells":2029},"68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2045,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2031,"activeCount":96},[],{"trials":2033,"activeCount":96},[2034],{"nctId":2035,"briefTitle":2036,"status":190,"phases":2037,"primaryCompletion":2038,"completion":2038,"start":2039,"enrollment":180,"conditions":2040,"interventions":2044},"NCT04849247","68Ga-DOTA-FAPI and 177Lu-DOTA-FAPI Theranostic Pair in Patients With Various Types of Cancer (Locally Advanced or Metastatic Cancer)",[84],"2024-04-15","2021-04-13",[2041,2042,2043],"177Lu-DOTA-FAPI","68Ga-DOTA-FAPI","Theranostic",[2028],{"trials":2046,"activeCount":96},[],{"trials":2048,"activeCount":96},[],{"trials":2050,"activeCount":96},[],{"trials":2052,"activeCount":96},[],{"intervention":2054,"totalTrials":92,"cells":2055},"177Lu-Dansyl-PSMA radioligand therapy",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2069,"PHASE3":2071,"PHASE4":2073,"NA":2075},{"trials":2057,"activeCount":96},[],{"trials":2059,"activeCount":96},[2060],{"nctId":2061,"briefTitle":2062,"status":1493,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":1009,"conditions":2066,"interventions":2068},"NCT06377683","Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer",[84],"2025-03-27","2024-04-05",[2067],"Metastatic Castration-resistant Prostate Cancer, mCRPC",[2054],{"trials":2070,"activeCount":96},[],{"trials":2072,"activeCount":96},[],{"trials":2074,"activeCount":96},[],{"trials":2076,"activeCount":96},[],{"intervention":2078,"totalTrials":92,"cells":2079},"177Lu-DOTA-EB-FAPI 1 radionuclide therapy",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2081,"activeCount":96},[],{"trials":2083,"activeCount":96},[2084],{"nctId":2085,"briefTitle":2086,"status":1493,"phases":2087,"primaryCompletion":2088,"completion":2064,"start":2089,"enrollment":2090,"conditions":2091,"interventions":2096},"NCT05410821","Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer",[84],"2024-06-15","2022-06-15",12,[2092,2093,2094,2095],"Refractory Thyroid Gland Carcinoma","Refractory Thyroid Gland Papillary Carcinoma","Refractory Thyroid Gland Follicular Carcinoma","Refractory Thyroid Gland Hurthle Cell Carcinoma",[2078,2097,2098],"177Lu-DOTA-EB-FAPI 2 radionuclide therapy","177Lu-DOTA-EB-FAPI 3 radionuclide therapy",{"trials":2100,"activeCount":96},[],{"trials":2102,"activeCount":96},[],{"trials":2104,"activeCount":96},[],{"trials":2106,"activeCount":96},[],{"intervention":2097,"totalTrials":92,"cells":2108},{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2117,"PHASE3":2119,"PHASE4":2121,"NA":2123},{"trials":2110,"activeCount":96},[],{"trials":2112,"activeCount":96},[2113],{"nctId":2085,"briefTitle":2086,"status":1493,"phases":2114,"primaryCompletion":2088,"completion":2064,"start":2089,"enrollment":2090,"conditions":2115,"interventions":2116},[84],[2092,2093,2094,2095],[2078,2097,2098],{"trials":2118,"activeCount":96},[],{"trials":2120,"activeCount":96},[],{"trials":2122,"activeCount":96},[],{"trials":2124,"activeCount":96},[],{"intervention":2098,"totalTrials":92,"cells":2126},{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2135,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2128,"activeCount":96},[],{"trials":2130,"activeCount":96},[2131],{"nctId":2085,"briefTitle":2086,"status":1493,"phases":2132,"primaryCompletion":2088,"completion":2064,"start":2089,"enrollment":2090,"conditions":2133,"interventions":2134},[84],[2092,2093,2094,2095],[2078,2097,2098],{"trials":2136,"activeCount":96},[],{"trials":2138,"activeCount":96},[],{"trials":2140,"activeCount":96},[],{"trials":2142,"activeCount":96},[],{"intervention":2144,"totalTrials":92,"cells":2145},"68Ga-FAPI",{"EARLY_PHASE1":2146,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2147,"activeCount":96},[2148],{"nctId":2149,"briefTitle":2150,"status":190,"phases":2151,"primaryCompletion":2152,"completion":2153,"start":2154,"enrollment":1037,"conditions":2155,"interventions":2158},"NCT05952531","Characterizing Myositis With 68Ga-FAPI PET\u002FCT",[83],"2024-07","2025-07","2023-07-01",[2156,2157],"Myositis","Idiopathic Inflammatory Myopathies",[2144],{"trials":2160,"activeCount":96},[],{"trials":2162,"activeCount":96},[],{"trials":2164,"activeCount":96},[],{"trials":2166,"activeCount":96},[],{"trials":2168,"activeCount":96},[],{"intervention":2170,"totalTrials":92,"cells":2171},"Apatinib\u002FCapecitatine",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[],{"trials":2177,"activeCount":96},[],{"trials":2179,"activeCount":96},[],{"trials":2181,"activeCount":96},[],{"trials":2183,"activeCount":96},[2184],{"nctId":2185,"briefTitle":2186,"status":190,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":924,"conditions":2191,"interventions":2193},"NCT03531931","Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial",[],"2023-05","2023-10","2018-05",[2192],"Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety",[2170],{"intervention":2195,"totalTrials":92,"cells":2196},"Thalidomide",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2205,"NA":2207},{"trials":2198,"activeCount":96},[],{"trials":2200,"activeCount":96},[],{"trials":2202,"activeCount":96},[],{"trials":2204,"activeCount":96},[],{"trials":2206,"activeCount":96},[],{"trials":2208,"activeCount":96},[2209],{"nctId":2210,"briefTitle":2211,"status":190,"phases":2212,"primaryCompletion":2213,"completion":1721,"start":2214,"enrollment":1454,"conditions":2215,"interventions":2217},"NCT01924624","Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma",[88],"2015-08","2013-07",[460,2216],"Recurrence",[2195],{"intervention":2219,"totalTrials":92,"cells":2220},"Take prebiotics and probiotics",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2222,"activeCount":96},[],{"trials":2224,"activeCount":96},[],{"trials":2226,"activeCount":96},[],{"trials":2228,"activeCount":96},[],{"trials":2230,"activeCount":96},[],{"trials":2232,"activeCount":96},[2233],{"nctId":2234,"briefTitle":2235,"status":190,"phases":2236,"primaryCompletion":2237,"completion":2237,"start":1583,"enrollment":1384,"conditions":2238,"interventions":2240},"NCT06277505","Efficacy and Safety Evaluation of Prebiotics Combined With Quadruple Probiotics in Improving Functional Constipation.",[88],"2025-06-01",[2239],"Functional Constipation",[2219],{"intervention":2242,"totalTrials":92,"cells":2243},"YISAIPU®",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2245,"activeCount":96},[],{"trials":2247,"activeCount":96},[],{"trials":2249,"activeCount":96},[],{"trials":2251,"activeCount":96},[],{"trials":2253,"activeCount":96},[],{"trials":2255,"activeCount":96},[2256],{"nctId":2257,"briefTitle":2258,"status":190,"phases":2259,"primaryCompletion":331,"completion":62,"start":2260,"enrollment":2261,"conditions":2262,"interventions":2264},"NCT05424393","Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients",[],"2022-03-04",500,[2263],"Rheumatoid Arthritis",[2242,2265],"csDMARDs",{"intervention":2265,"totalTrials":92,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2269,"activeCount":96},[],{"trials":2271,"activeCount":96},[],{"trials":2273,"activeCount":96},[],{"trials":2275,"activeCount":96},[],{"trials":2277,"activeCount":96},[],{"trials":2279,"activeCount":96},[2280],{"nctId":2257,"briefTitle":2258,"status":190,"phases":2281,"primaryCompletion":331,"completion":62,"start":2260,"enrollment":2261,"conditions":2282,"interventions":2283},[],[2263],[2242,2265]]